(NUS) Nu Skin Enterprises - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US67018T1051
Stock: Skincare Devices, Cosmetics, Supplements, Collagen, Weight Management
Total Rating 63
Risk 99
Buy Signal -1.22
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.58% |
| Yield on Cost 5y | 0.49% |
| Yield CAGR 5y | -36.96% |
| Payout Consistency | 96.5% |
| Payout Ratio | 7.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 54.6% |
| Relative Tail Risk | -11.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.98 |
| Alpha | 41.78 |
| Character TTM | |
|---|---|
| Beta | 0.975 |
| Beta Downside | 1.333 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.76% |
| CAGR/Max DD | -0.41 |
Description: NUS Nu Skin Enterprises December 28, 2025
Nu Skin Enterprises, Inc. (NYSE: NUS) develops and distributes a portfolio of beauty and wellness products-including ageLOC LumiSpa devices, Pharmanex nutritional supplements, and the ageLOC TR90 weight-management system-through a hybrid model of direct-seller networks, e-commerce, and retail outlets under the Nu Skin, Pharmanex, and ageLOC brands.
For FY 2023 the company reported net sales of $2.0 billion, a 5 % YoY increase driven primarily by higher e-commerce penetration (online sales grew ~12 % year-over-year) and expansion in the Asia-Pacific direct-seller base, which now exceeds 1.2 million active distributors. The personal-care sector’s growth is underpinned by rising consumer spending on anti-aging and health-supplement products, while macro-level factors such as discretionary income trends and regulatory scrutiny of supplement claims remain material risks.
If you’re looking to deepen the quantitative analysis, ValueRay’s platform provides granular, real-time KPI dashboards that can help you assess Nu Skin’s valuation dynamics more precisely.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 109.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.99 > 1.0 |
| NWC/Revenue: 18.82% < 20% (prev 17.69%; Δ 1.13% < -1%) |
| CFO/TA 0.06 > 3% & CFO 89.5m > Net Income 109.6m |
| Net Debt (39.6m) to EBITDA (191.8m): 0.21 < 3 |
| Current Ratio: 2.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.3m) vs 12m ago 1.16% < -2% |
| Gross Margin: 67.20% > 18% (prev 0.71%; Δ 6649 % > 0.5%) |
| Asset Turnover: 103.8% > 50% (prev 112.1%; Δ -8.37% > 0%) |
| Interest Coverage Ratio: 8.60 > 6 (EBITDA TTM 191.8m / Interest Expense TTM 15.8m) |
Altman Z'' 9.10
| A: 0.21 (Total Current Assets 548.1m - Total Current Liabilities 254.4m) / Total Assets 1.42b |
| B: 1.30 (Retained Earnings 1.85b / Total Assets 1.42b) |
| C: 0.09 (EBIT TTM 136.0m / Avg Total Assets 1.50b) |
| D: 2.77 (Book Value of Equity 1.73b / Total Liabilities 624.6m) |
| Altman-Z'' Score: 9.10 = AAA |
Beneish M -3.16
| DSRI: 0.81 (Receivables 48.9m/68.8m, Revenue 1.56b/1.78b) |
| GMI: 1.05 (GM 67.20% / 70.70%) |
| AQI: 1.08 (AQ_t 0.30 / AQ_t-1 0.27) |
| SGI: 0.88 (Revenue 1.56b / 1.78b) |
| TATA: 0.01 (NI 109.6m - CFO 89.5m) / TA 1.42b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of NUS shares?
As of February 01, 2026, the stock is trading at USD 10.61 with a total of 435,478 shares traded.
Over the past week, the price has changed by -4.07%, over one month by +9.27%, over three months by +0.48% and over the past year by +57.12%.
Over the past week, the price has changed by -4.07%, over one month by +9.27%, over three months by +0.48% and over the past year by +57.12%.
Is NUS a buy, sell or hold?
Nu Skin Enterprises has no consensus analysts rating.
What are the forecasts/targets for the NUS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.5 | -29.3% |
| Analysts Target Price | 7.5 | -29.3% |
| ValueRay Target Price | 8.9 | -16.1% |
NUS Fundamental Data Overview January 27, 2026
P/E Trailing = 4.4658
P/E Forward = 7.7882
P/S = 0.3455
P/B = 0.6741
P/EG = 2.35
Revenue TTM = 1.56b USD
EBIT TTM = 136.0m USD
EBITDA TTM = 191.8m USD
Long Term Debt = 209.0m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 291.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.6m USD (from netDebt column, last quarter)
Enterprise Value = 516.4m USD (476.8m + Debt 291.4m - CCE 251.8m)
Interest Coverage Ratio = 8.60 (Ebit TTM 136.0m / Interest Expense TTM 15.8m)
EV/FCF = 9.68x (Enterprise Value 516.4m / FCF TTM 53.4m)
FCF Yield = 10.33% (FCF TTM 53.4m / Enterprise Value 516.4m)
FCF Margin = 3.42% (FCF TTM 53.4m / Revenue TTM 1.56b)
Net Margin = 7.02% (Net Income TTM 109.6m / Revenue TTM 1.56b)
Gross Margin = 67.20% ((Revenue TTM 1.56b - Cost of Revenue TTM 511.8m) / Revenue TTM)
Gross Margin QoQ = 70.49% (prev 68.82%)
Tobins Q-Ratio = 0.36 (Enterprise Value 516.4m / Total Assets 1.42b)
Interest Expense / Debt = 1.42% (Interest Expense 4.14m / Debt 291.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 107.5m (EBIT 136.0m * (1 - 21.00%))
Current Ratio = 2.15 (Total Current Assets 548.1m / Total Current Liabilities 254.4m)
Debt / Equity = 0.36 (Debt 291.4m / totalStockholderEquity, last quarter 799.8m)
Debt / EBITDA = 0.21 (Net Debt 39.6m / EBITDA 191.8m)
Debt / FCF = 0.74 (Net Debt 39.6m / FCF TTM 53.4m)
Total Stockholder Equity = 748.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.29% (Net Income 109.6m / Total Assets 1.42b)
RoE = 14.65% (Net Income TTM 109.6m / Total Stockholder Equity 748.2m)
RoCE = 14.21% (EBIT 136.0m / Capital Employed (Equity 748.2m + L.T.Debt 209.0m))
RoIC = 10.48% (NOPAT 107.5m / Invested Capital 1.03b)
WACC = 6.33% (E(476.8m)/V(768.2m) * Re(9.51%) + D(291.4m)/V(768.2m) * Rd(1.42%) * (1-Tc(0.21)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.84%
[DCF Debug] Terminal Value 81.13% ; FCFF base≈68.3m ; Y1≈52.5m ; Y5≈32.8m
Fair Price DCF = 17.50 (EV 893.0m - Net Debt 39.6m = Equity 853.3m / Shares 48.8m; r=6.33% [WACC]; 5y FCF grow -27.52% → 2.90% )
EPS Correlation: -24.58 | EPS CAGR: -54.87% | SUE: -0.49 | # QB: 0
Revenue Correlation: -95.61 | Revenue CAGR: -15.12% | SUE: -0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.27 | Chg30d=-0.050 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.42 | Chg30d=-0.140 | Revisions Net=-1 | Growth EPS=+9.2% | Growth Revenue=+2.1%
P/E Forward = 7.7882
P/S = 0.3455
P/B = 0.6741
P/EG = 2.35
Revenue TTM = 1.56b USD
EBIT TTM = 136.0m USD
EBITDA TTM = 191.8m USD
Long Term Debt = 209.0m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 291.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.6m USD (from netDebt column, last quarter)
Enterprise Value = 516.4m USD (476.8m + Debt 291.4m - CCE 251.8m)
Interest Coverage Ratio = 8.60 (Ebit TTM 136.0m / Interest Expense TTM 15.8m)
EV/FCF = 9.68x (Enterprise Value 516.4m / FCF TTM 53.4m)
FCF Yield = 10.33% (FCF TTM 53.4m / Enterprise Value 516.4m)
FCF Margin = 3.42% (FCF TTM 53.4m / Revenue TTM 1.56b)
Net Margin = 7.02% (Net Income TTM 109.6m / Revenue TTM 1.56b)
Gross Margin = 67.20% ((Revenue TTM 1.56b - Cost of Revenue TTM 511.8m) / Revenue TTM)
Gross Margin QoQ = 70.49% (prev 68.82%)
Tobins Q-Ratio = 0.36 (Enterprise Value 516.4m / Total Assets 1.42b)
Interest Expense / Debt = 1.42% (Interest Expense 4.14m / Debt 291.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 107.5m (EBIT 136.0m * (1 - 21.00%))
Current Ratio = 2.15 (Total Current Assets 548.1m / Total Current Liabilities 254.4m)
Debt / Equity = 0.36 (Debt 291.4m / totalStockholderEquity, last quarter 799.8m)
Debt / EBITDA = 0.21 (Net Debt 39.6m / EBITDA 191.8m)
Debt / FCF = 0.74 (Net Debt 39.6m / FCF TTM 53.4m)
Total Stockholder Equity = 748.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.29% (Net Income 109.6m / Total Assets 1.42b)
RoE = 14.65% (Net Income TTM 109.6m / Total Stockholder Equity 748.2m)
RoCE = 14.21% (EBIT 136.0m / Capital Employed (Equity 748.2m + L.T.Debt 209.0m))
RoIC = 10.48% (NOPAT 107.5m / Invested Capital 1.03b)
WACC = 6.33% (E(476.8m)/V(768.2m) * Re(9.51%) + D(291.4m)/V(768.2m) * Rd(1.42%) * (1-Tc(0.21)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.84%
[DCF Debug] Terminal Value 81.13% ; FCFF base≈68.3m ; Y1≈52.5m ; Y5≈32.8m
Fair Price DCF = 17.50 (EV 893.0m - Net Debt 39.6m = Equity 853.3m / Shares 48.8m; r=6.33% [WACC]; 5y FCF grow -27.52% → 2.90% )
EPS Correlation: -24.58 | EPS CAGR: -54.87% | SUE: -0.49 | # QB: 0
Revenue Correlation: -95.61 | Revenue CAGR: -15.12% | SUE: -0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.27 | Chg30d=-0.050 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.42 | Chg30d=-0.140 | Revisions Net=-1 | Growth EPS=+9.2% | Growth Revenue=+2.1%